Profitelligence Profitelligence · Filing Ledger Open HALO research →

Form 8-K · Current Report · Filed 2025-03-21

Halozyme Therapeutics Announces CTO Retirement

On March 17, 2025, Michael J. LaBarre, Senior Vice President and Chief Technical Officer of Halozyme Therapeutics, Inc., announced his retirement effective the same day. The company thanked Mr. LaBarre for his contributions to the ENHANZE drug delivery technology.

Filer
Halozyme Therapeutics Inc. HALO · NASDAQ
Filed
Accession
0001159036-25-000020
CIK
0001159036
Signal
Medium impactHealthcare

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

CTO Resignation

Market reaction

Close before filing

$64.32

Next session

-0.5%

Since filing

+71.4%

Latest close

$110.24

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from HALO reporting the same item, with the next session's move:

Board Member Connie L. Matsui Not Standing for Reelection+0.3%

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.

Exchange NASDAQ Industry Biotechnology Company website ↗

Never miss another HALO filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts